Unicycive Issuance Of Capital Stock from 2010 to 2025

UNCY Stock  USD 0.62  0.01  1.64%   
Unicycive Therapeutics Issuance Of Capital Stock yearly trend continues to be fairly stable with very little volatility. Issuance Of Capital Stock is likely to outpace its year average in 2025. During the period from 2010 to 2025, Unicycive Therapeutics Issuance Of Capital Stock regression line of annual values had r-squared of  0.53 and arithmetic mean of  8,467,679. View All Fundamentals
 
Issuance Of Capital Stock  
First Reported
2010-12-31
Previous Quarter
34.7 M
Current Value
36.5 M
Quarterly Volatility
13.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 89.6 K, Net Interest Income of 493.9 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Unicycive Therapeutics Correlation against competitors.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Latest Unicycive Therapeutics' Issuance Of Capital Stock Growth Pattern

Below is the plot of the Issuance Of Capital Stock of Unicycive Therapeutics over the last few years. It is Unicycive Therapeutics' Issuance Of Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Issuance Of Capital Stock10 Years Trend
Slightly volatile
   Issuance Of Capital Stock   
       Timeline  

Unicycive Issuance Of Capital Stock Regression Statistics

Arithmetic Mean8,467,679
Geometric Mean1,724,841
Coefficient Of Variation161.66
Mean Deviation11,225,018
Median1,166,000
Standard Deviation13,688,522
Sample Variance187.4T
Range36.5M
R-Value0.73
Mean Square Error95.2T
R-Squared0.53
Significance0
Slope2,084,518
Total Sum of Squares2810.6T

Unicycive Issuance Of Capital Stock History

202536.5 M
202434.7 M
202330.2 M
202211 K
202122.3 M
2020141 K

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Issuance Of Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Issuance Of Capital Stock34.7 M36.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.